TECARTUS™ is the first and only FDA-approved CAR T-cell therapy
for adult patients with relapsed or refractory mantle cell lymphoma1,2

87% ORR (n=52/60)2

DEEP

CR: 62% (n=37/60)2

DURABLE

The median duration of response was not reached at a median study follow-up of 12.3 months2,4

RAPID

1 month median time to response (range: 0.8–3.1 months)2

BTKi=Bruton’s tyrosine kinase inhibitor; CAR=chimeric antigen receptor; CR=complete response; DOR=duration of response; ORR=objective response rate; PFS=progression-free survival.

References: 1. Kite, a Gilead Company [press release]. U.S. FDA approves Kite's TECARTUS™, the first and only CAR T treatment for relapsed or refractory mantle cell lymphoma. Published July 24, 2020. https://www.businesswire.com/news/home/20200724005428/en/U.S.-FDA-Approves-Kite%E2%80%99s-Tecartus%E2%84%A2-CAR-Treatment. Accessed July 24, 2020. 2. TECARTUS™ (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2020. 3. Data on file [1]. Kite Pharma, Inc; 2020. 4. Data on file [2]. Kite Pharma, Inc; 2020. 5. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle cell lymphoma. N Engl J Med. 2020;382(14):1331-1342.